Use of topical clotrimazole in human keratomycosis.
Twelve out of 15 patients (9 males and 6 females) with laboratory-proven fungal keratitis were treated with topical clotrimazole, a synthetic imidazole derivative. Their ages ranged from 8 to 70 years. The posttreatment visual acuities were significantly better than the pretreatment visual acuities. No significant biomicroscopic signs of ocular surface toxicity were noted. The ocular condition in 3 patients (all infected with Fusarium solani) deteriorated to blindness despite the antifungal therapy.


CONCLUSIONS
The clotrimazole usually marketed as dermatological preparation can be used in a diluted form to treat human keratomycosis safely and successfully. A combination with a polyene derivative should be considered in the treatment of fungal corneal infection due to Fusarium spp.
Mselle
J
J
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D002648:Child; D003022:Clotrimazole / Q000627:therapeutic use*; D003315:Cornea / Q000382:microbiology; D003316:Corneal Diseases / Q000188:drug therapy* / Q000382:microbiology; D015821:Eye Infections, Fungal / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D005658:Fungi / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology
D000935:Antifungal Agents; D003022:Clotrimazole